Sanofi
Aïcha, a French patient and mother of two lives with autoimmune T1D

Aïcha, a French patient and mother of two lives with autoimmune T1D

Aïcha, a French patient and mother of two lives with autoimmune T1D

Understanding Autoimmune Type 1 Diabetes (T1D)

Symptoms, Stages & Early Diagnosis

We are dedicated to supporting the autoimmune type 1 diabetes community by exploring innovative therapies that have the potential to improve outcomes for millions of people living with the condition.
Thomas Grenier

Thomas Grenier

Executive Vice President, General Medicines

What is Type 1 Diabetes?

A woman sits at an outdoor table with two teenagers, all three smiling and looking at a laptop together.
Aïcha and her sons, Tibere and Aylan, all living with autoimmune T1D

Type 1 diabetes (T1D) is a lifelong, progressive autoimmune disease that occurs when the immune system mistakenly attacks the insulin-producing cells (beta cells) in the pancreas.1

Insulin allows the sugar in our blood to be used by our cells and organs for energy. 2,3 As beta cells are damaged, insulin production declines and the body become less able to regulate blood sugar levels. People with symptomatic T1D will then require lifelong insulin treatment to replace the insulin that is no longer being produced by the body.4

Key Facts About Type 1 Diabetes

9.2 million people worldwide live with type 1 diabetes,4,5 which is expected to increase to 17.4 million by 2040.6

Although often diagnosed in childhood, type 1 diabetes can develop at any age. Nearly 60% of type 1 diabetes cases develop during adulthood,7 and around 90% of people have no family history.8

Type 1 diabetes can begin months or years before symptoms appear.9

Common signs of symptomatic type 1 diabetes may include the following symptoms: increased thirst, fatigue, unexplained weight loss and frequent urination.4 For more information on symptoms visit our FAQ. 

Understanding the Stages of Type 1 Diabetes

Stage 1

The immune system is attacking insulin-producing cells (beta cells), at least two or more autoantibodies (AAb) are present, but blood sugar levels remain within a normal range (normoglycemia). At this stage, patients would not experience any symptoms.4,10

How is Type 1 Diabetes Diagnosed?

A healthcare professional measures a patient’s blood pressure using a manual cuff during a clinical check-up.
Routine health checks are a cornerstone for early diagnosis.

When the attack on the insulin-producing beta cells begins, the body will produce T1D autoantibodies, where the appearance of these in the blood is a typical sign of the insulin producing cells being affected.4

Most people with autoimmune type 1 diabetes (T1D) are diagnosed at stage 3 when symptoms appear and the risk of serious complications increases.4

Once two or more T1D autoantibodies are detected, there are several tests used to monitor blood sugar levels. Please see FAQ for further detail on the types of tests available.

What is Diabetic Ketoacidosis (DKA)?

  • Depending on the country and age at diagnosis, up to 80% of people experience diabetic ketoacidosis (DKA) at diagnosis.12
     
  • DKA is a serious complication caused by a lack of insulin, where the body is unable to use the sugar in the blood for energy and instead breaks down fat for fuel.13 This process makes the blood acidic and harmful due to chemicals released called ketones.13
     
  • DKA often requires intensive care in hospital and has been linked to effects on cognitive function and brain development as well as difficulties in managing glycemic control, leading to increased risk of complications.4,14,15,16

For more information on the DKA symptoms visit our FAQ below. 

Benefits of Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) can be detected in its early stages before symptoms appear. In the early stages of T1D, the immune system produces autoantibodies, which can be detected through a blood sample before symptoms appear.17

Early detection of T1D has several objectives:

  • To give people and families more time to prepare, seek medical and psychological support, get answers to their questions, discuss the implementation of treatment if applicable, and adjust to living with autoimmune type 1 diabetes, before it requires daily and lifelong management.8,18
  • To reduce the risk of serious complications such as diabetic ketoacidosis (DKA) at diagnosis, as timely intervention and education can help people manage rising blood sugar levels.8
  • To provide opportunities to enroll in clinical trials for innovative therapies.19

To help avoid misdiagnosis, the symptoms of stage 3 type 1 diabetes can resemble other conditions, such as type 2 diabetes. Distinguishing between T1D and T2D can be particularly challenging particularly in adults.10,20

Leveraging Our Heritage to Revolutionize the Future

A scientist is seen in a lab
Elke Blansaer, Scientist from Belgium

At Sanofi, we are redefining immunology from science to treatment. Building on 100 years of expertise in diabetes, we continue to push scientific boundaries to improve our understanding of the immune system. We then put this knowledge to work in developing future medicines tailored to the needs of people living with autoimmune T1D. Discover Xavier’s inspiring storyof living with autoimmune type 1 diabetes.

Explore More

A patient sitting in the waiting area of Buguruni Angelical Health Center, Dar es Salaam, Tanzania.

Diabetes and Cardiovascular Diseases: A Global Public Health Concern

Melissa, living with type 1 diabetes

Breaking Barriers in Diabetes, Transforming Care Together

Illustration T1D

Advancing the Science in Autoimmune Type 1 Diabetes

FAQ About Autoimmune Type 1 Diabetes

What are the common signs and symptoms?

Common symptoms of type 1 diabetes include: increased thirst, fatigue, unexplained weight loss, and frequent urination.4 For some additional signs and symptoms associated with DKA this can include: fruit-smelling breath, stomach pain, feeling or being sick, high blood sugar levels, and confusion.13 

References

  1. Diabetes. Beta Cells. Available at: https://www.diabetes.co.uk/body/beta-cells.html. Last accessed: October 2026.
  2. Powers AC. Type 1 diabetes mellitus: much progress, many opportunities. J Clin Invest. 2021;131(8):e142242.​
  3. Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, Hannan MA, Uddin MJ, Pang MG. Role of Insulin in Health and Disease: An Update. Int J Mol Sci. 2021 Jun 15;22(12):6403​
  4. Insel RA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974
  5. International Diabetes Federation. Type 1 Diabetes. Available at: https://idf.org/about-diabetes/type-1-diabetes/. Last accessed: October 2026.
  6. Gregory GA. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022 Oct;10(10):741-760
  7. Ogle GD, Wang F, Haynes A, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0. Diabetes Res Clin Pract. 2025 Jul;225:112277. 
  8. Sims EK, et al. Screening for type 1 diabetes in the general population: A Status Report and Perspective. Diabetes. 2022;71(4):610-623.
  9. Maddaloni E, et al. C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective. Diabetes Obes Metab. 2022;24(10):1912-1926.
  10. DiMeglio LA, Evans-Molina C and Oram RA. Type 1 diabetes. Lancet. 2018;391(10138):2449-2462
  11. Breakthrough T1D. The stages of type 1 diabetes. Available at: https://breakthrought1d.org.au/what-is-t1d/stages/. Last accessed: October 2026.
  12. Usher-Smith, J.A., Thompson, M., Ercole, A. et al. Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review. Diabetologia. 2012; 55, 2878–2894.
  13. Diabetes UK. What is DKA (Diabetic Ketoacidosis)? Available at: https://www.diabetes.org.uk/guide-to-diabetes/complications/diabetic_ketoacidosis. Last accessed: October 2026.
  14. Elendu C et al. Comprehensive review of diabetic ketoacidosis: an update. Ann Med Surg (Lond). 2023;85(6): 2802–2807.
  15. Aye T, et al. Impact of Early Diabetic Ketoacidosis on the Developing Brain. Diabetes Care. 2019;42(3):443-9.
  16. Brandstaetter E. et al. Recurrent diabetic ketoacidosis. Arch Endocrinol Metab. 2019. 63(5): 531–535.
  17. Raab J et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open. 2016;6:e011144.
  18. Narendran P. Screening for type 1 diabetes: are we nearly there yet? Diabetologia. 2019;62(1):24-27.
  19. Simmons KMW, et al. Historical Insights and Current Perspectives on the Diagnosis and Management of Presymptomatic Type 1 Diabetes DiabetesTechnol Ther. 2023;25(11):790-9.
  20. The Lancet Regional Health – Europe. Misdiagnosis of type 1 and type 2 diabetes in adults. The Lancet Regional Health – Europe, 29
  21. Besser REJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2022;1-13. ​
  22. Mezza T, et al. Diabetes. 2019; 68: 1121–1129.
  23. Parkkola A et al. Extended Family History of Type 1 Diabetes and Phenotype and Genotype of Newly Diagnosed Children. Diabetes Care. 2013; 36(2): 348–354.​
  24. Popoviciu MS et al. Type 1 Diabetes Mellitus and Autoimmune Diseases: A Critical Review of the Association and the Application of Personalized Medicine. J Pers Med. 2023;13(3):422.​
  25. Cameron FJ, et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care. 2014;37(6):1554-62.​
MAT-GLB-2605389 – 3.0 - 10/2026